Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study

被引：0

作者：

Corren, J. ^{[1
]}

Garcia Gil, E. ^{[2
]}

Parnes, J. R. ^{[3
]}

Pham, T. ^{[4
]}

Griffiths, J. M. ^{[4
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] AstraZeneca, Barcelona, Spain

[3] Amgen Inc, Thousand Oaks, CA 91320 USA

[4] MedImmune, Gaithersburg, MD USA

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A2621

引用

页数：2

共 2 条

[1] Tezepelumab in Adults with Uncontrolled Asthma [J].

Corren, Jonathan ;

Parnes, Jane R. ;

Wang, Liangwei ;

Mo, May ;

Roseti, Stephanie L. ;

Griffiths, Janet M. ;

van der Merwe, Rene .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (10) :936-946

[2] Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses [J].

Gauvreau, Gail M. ;

O'Byrne, Paul M. ;

Boulet, Louis-Philippe ;

Wang, Ying ;

Cockcroft, Donald ;

Bigler, Jeannette ;

FitzGerald, J. Mark ;

Boedigheimer, Michael ;

Davis, Beth E. ;

Dias, Clapton ;

Gorski, Kevin S. ;

Smith, Lynn ;

Bautista, Edgar ;

Comeau, Michael R. ;

Leigh, Richard ;

Parnes, Jane R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2102-2110

← 1 →